IgM anti-MAG paraproteinaemic neuropathy: treatment
Evidence-based neurology checklist on igm anti-mag paraproteinaemic neuropathy: treatment: Rituximab This is possibly the best treatment Benefit is reported in 30-50% of cases The best response is with sensory deficits and high antibody levels Good response is also seen in those with proximal…
Rituximab
- This is possibly the best treatment
- Benefit is reported in 30-50% of cases
- The best response is with sensory deficits and high antibody levels
- Good response is also seen in those with proximal lower limb weakness at onset
- The effect is sustained for up to two years
- It can cause paradoxical worsening of neuropathy
Plasma exchange
Investigational treatments: Ibrutinib
Investigational treatments: others
Other treatments: with minimal benefit
Conservative treatment: for mild symptoms
Conservative treatment: for mild symptoms
Acronyms
References
- Dalakas MC. Pathogenesis and treatment of anti-MAG neuropathy. Curr Treat Options Neurol 2010; 12:71-83.
- Dalakas MC. Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies. Ther Adv Neurol Disord 2018; 11:1756285617746640.
- So YT. Immune-mediated neuropathies. Continuum (Minneap Minn) 2012; 18:85-105.
- Svahn J, Petiot P, Antoine JC, et al; Francophone anti-MAG cohort Group. Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features. JNNP 2018; 89:499-505.
- Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in IgM anti-myelin, associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009; 65:286-293.
- And 10 more. Subscribe to see the full list
